Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
YMAB

YMAB - Y-mAbs Therapeutics Inc Stock Price, Fair Value and News

11.91USD-0.14 (-1.16%)Market Closed

Market Summary

YMAB
USD11.91-0.14
Market Closed
-1.16%

YMAB Alerts

  • 2 major insider sales recently.
  • Losses in recent quarter

YMAB Stock Price

View Fullscreen

YMAB RSI Chart

YMAB Valuation

Market Cap

528.8M

Price/Earnings (Trailing)

-24.41

Price/Sales (Trailing)

6.26

EV/EBITDA

-22.39

Price/Free Cashflow

-30.07

YMAB Price/Sales (Trailing)

YMAB Profitability

EBT Margin

-24.79%

Return on Equity

-21.84%

Return on Assets

-17.57%

Free Cashflow Yield

-3.33%

YMAB Fundamentals

YMAB Revenue

Revenue (TTM)

84.5M

Rev. Growth (Yr)

-1.58%

Rev. Growth (Qtr)

-14.69%

YMAB Earnings

Earnings (TTM)

-21.7M

Earnings Growth (Yr)

-3.74%

Earnings Growth (Qtr)

-570.95%

Breaking Down YMAB Revenue

Last 7 days

-2.0%

Last 30 days

2.0%

Last 90 days

-18.0%

Trailing 12 Months

41.7%

How does YMAB drawdown profile look like?

YMAB Financial Health

Current Ratio

6.15

YMAB Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202484.5M000
202375.0M85.0M92.9M84.8M
202240.0M39.8M43.4M65.3M
202129.2M37.6M46.0M34.9M
202000020.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Y-mAbs Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 11, 2024
gill david n
acquired
-
-
3,495
-
Jun 11, 2024
wedell-wedellsborg johan
acquired
-
-
3,495
-
Jun 11, 2024
tyagi ashu
acquired
-
-
3,495
-
Jun 11, 2024
tagliaferri mary
acquired
-
-
3,495
-
Jun 11, 2024
healy james
acquired
-
-
3,495
-
Jun 11, 2024
hamill laura
acquired
-
-
3,495
-
Jun 11, 2024
gad thomas
sold
-420,000
12.00
-35,000
chief business officer
Jun 10, 2024
gad thomas
sold
-421,050
12.03
-35,000
chief business officer
Jun 10, 2024
ber gerard
sold
-8,664
12.00
-722
-
May 31, 2024
kruse bo
sold
-378,648
12.07
-31,371
evp, cfo, secry & treas.

1–10 of 50

Which funds bought or sold YMAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 28, 2024
Boston Partners
new
-
555,520
555,520
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.14
102,421
136,421
0.02%
May 16, 2024
JANE STREET GROUP, LLC
added
211
1,414,220
1,634,420
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.9
18,860
60,162
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
new
-
615,294
615,294
-%
May 15, 2024
Point72 Asset Management, L.P.
new
-
24,830,600
24,830,600
0.06%
May 15, 2024
Cubist Systematic Strategies, LLC
added
109
1,011,700
1,264,800
0.01%
May 15, 2024
BOOTHBAY FUND MANAGEMENT, LLC
reduced
-50.08
900,548
5,634,270
0.11%
May 15, 2024
Sofinnova Investments, Inc.
unchanged
-
20,714,000
35,679,000
1.99%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-49.36
9,459
55,057
-%

1–10 of 48

Are Funds Buying or Selling YMAB?

Are funds buying YMAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own YMAB
No. of Funds

Unveiling Y-mAbs Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 08, 2024
paradigm biocapital advisors lp
5.02%
2,198,312
SC 13G
Feb 14, 2024
wg biotech aps
10.4%
4,559,233
SC 13G/A
Feb 13, 2024
hbm healthcare investments (cayman) ltd.
7.6%
3,297,800
SC 13G/A
Feb 13, 2024
vanguard group inc
5.14%
2,244,238
SC 13G/A
Feb 06, 2024
acorn bioventures, l.p.
2.7%
1,159,966
SC 13G/A
Jan 26, 2024
blackrock inc.
6.7%
2,917,080
SC 13G/A
Apr 03, 2023
acorn bioventures, l.p.
2.2%
977,142
SC 13G
Feb 14, 2023
wg biotech aps
9.6%
4,178,465
SC 13G
Feb 14, 2023
hbm healthcare investments (cayman) ltd.
8.7%
3,813,853
SC 13G/A
Feb 09, 2023
vanguard group inc
5.17%
2,258,254
SC 13G

Recent SEC filings of Y-mAbs Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 13, 2024
8-K
Current Report
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Y-mAbs Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
13.11% 15.14%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.19% -19.39%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
5.74% -10.79%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
9.90% 2.05%
18.71
3.7
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.65% 94.95%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
22.84% 567.64%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-17.34% 57.33%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Y-mAbs Therapeutics Inc News

Latest updates
Simply Wall St11 hours ago

Y-mAbs Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue-14.7%19,931,00023,363,00020,454,00020,751,00020,251,00031,447,00012,537,00010,797,00010,486,0009,598,0008,965,00010,951,0005,383,00020,750,000
Costs and Expenses1.0%26,839,00026,562,00028,203,00027,974,00027,752,00032,600,50038,554,00050,742,00038,181,00045,356,00037,669,00033,663,00033,642,00040,844,500
Operating Expenses--------------40,844,500
  S&GA Expenses2.6%11,425,00011,135,00010,200,00011,270,00012,251,00010,793,00013,626,00023,082,00013,438,00015,138,00013,988,00013,475,00011,970,00014,630,500
  R&D Expenses-0.9%13,267,00013,388,00015,358,00012,055,00013,418,00019,787,00022,453,00026,420,00022,912,00028,757,00023,131,00019,778,00021,579,00024,011,000
EBITDA Margin-0.9%-0.24-0.24-1.02-1.11-1.26-1.45--------
Income Taxes-17.9%160,000195,000187,000179,000----------
Earnings Before Taxes-715.8%-6,469,000-793,000-7,560,000-6,123,000-6,390,000--27,526,000-41,131,000------
EBT Margin-0.8%-0.25-0.25-1.03-1.12-1.27-1.46--------
Net Income-571.0%-6,629,000-988,000-7,747,000-6,302,000-6,390,0001,157,000-27,526,000-41,131,000-28,068,000-36,893,000-28,858,000-22,937,00033,413,000-19,933,000
Net Income Margin-1.5%-0.26-0.25-0.21-0.46-0.98-1.46-3.08-3.39-2.92-1.58-0.83-1.12-2.05-
Free Cashflow56.7%-3,477,000-8,036,000-1,493,000-4,889,000-13,279,000-8,816,000-19,390,000-23,255,000-25,080,000-34,018,000-18,147,000-18,797,000-32,261,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-3.6%123128129132137141144165191213240259275132143167194216104126140
  Current Assets-2.6%108111115116124130133154178202231249264122133163190212100123137
    Cash Equivalents-3.7%76.0079.0087.0088.0093.0010611513415718221623425211513115818620798.00120134
  Inventory66.8%8.005.007.005.009.007.006.007.006.006.005.004.001.00--------
  Net PPE-31.7%0.000.000.000.001.001.001.002.002.002.002.002.002.002.002.002.002.002.002.000.000.00
Liabilities-10.3%24.0027.0029.0028.0030.0032.0036.0034.0034.0033.0029.0025.0023.0026.0027.0021.0019.0017.0018.0018.0014.00
  Current Liabilities-12.5%18.0020.0022.0024.0026.0028.0032.0029.0029.0028.0025.0021.0017.0020.0020.0016.0015.0014.0014.0014.0010.00
Shareholder's Equity-1.8%99.0010110010510810910813115718021123425210611714617519986.00108126
  Retained Earnings-1.4%-464-457-456-448-442-436-437-409-368-340-303-274-251-285-265-232-192-165-142-118-100
  Additional Paid-In Capital0.8%562558555552549544540538524519514509504392382378367365229227226
Shares Outstanding0.4%44.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0043.0042.00--------
Float----246---551---1,000---990---296-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations56.7%-3,477-8,036-1,338-4,734-13,124-8,661-19,235-23,100-24,925-33,863-18,076-18,756-31,861-17,695-24,145-27,635-21,756-24,579-21,395-14,040-13,483
  Share Based Compensation23.2%3,8463,1232,4103,6165,3043,5373,34113,6335,0914,9084,9014,8274,6988,3363,1342,4542,2111,4771,345971864
Cashflow From Investing-----------455-71.00-41.0061,610-44.00-2,713-2.00-26.00-1,147-617-75.00-126
Cashflow From Financing-588-----52.00-32.00100248131107,8351,419215-370----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

YMAB Income Statement

2024-03-31
Consolidated Statements of Net Loss and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
REVENUES  
Total revenues$ 19,931$ 20,251
OPERATING COSTS AND EXPENSES  
Cost of goods sold2,0972,083
License royalties50 
Research and development13,26713,418
Selling, general, and administrative11,42512,251
Total operating costs and expenses26,83927,752
Loss from operations(6,908)(7,501)
OTHER INCOME, NET  
Interest and other income4391,111
LOSS BEFORE INCOME TAXES(6,469)(6,390)
Provision for income taxes160 
NET LOSS(6,629)(6,390)
Other comprehensive income/(loss)  
Foreign currency translation399(306)
COMPREHENSIVE LOSS$ (6,230)$ (6,696)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.15)$ (0.15)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.15)$ (0.15)
Weighted average common shares outstanding, basic (in shares)43,779,45643,671,589
Weighted average common shares outstanding, diluted (in shares)43,779,45643,671,589
Product  
REVENUES  
Total revenues$ 19,431$ 20,251
License  
REVENUES  
Total revenues$ 500 

YMAB Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 75,749$ 78,637
Accounts receivable, net20,58822,454
Inventories8,4485,065
Other current assets3,4824,955
Total current assets108,267111,111
Property and equipment, net153224
Operating lease right-of-use assets1,1791,412
Intangible assets, net2,5432,631
Other assets11,17312,491
TOTAL ASSETS123,315127,869
LIABILITIES  
Accounts payable6,7286,060
Accrued liabilities9,98913,166
Operating lease liabilities, current portion888902
Total current liabilities17,60520,128
Accrued milestone and royalty payments5,3755,375
Operating lease liabilities, long-term portion293517
Other liabilities853864
TOTAL LIABILITIES24,12626,884
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY  
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 43,852,638 and 43,672,112 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively44
Additional paid-in capital562,436558,002
Accumulated other comprehensive income848449
Accumulated deficit(464,099)(457,470)
TOTAL STOCKHOLDERS' EQUITY99,189100,985
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 123,315$ 127,869
YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
 CEO
 WEBSITEymabs.com
 INDUSTRYBiotechnology
 EMPLOYEES147

Y-mAbs Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Y-mAbs Therapeutics Inc? What does YMAB stand for in stocks?

YMAB is the stock ticker symbol of Y-mAbs Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Y-mAbs Therapeutics Inc (YMAB)?

As of Thu Jun 13 2024, market cap of Y-mAbs Therapeutics Inc is 528.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers.

What is the fair value of YMAB stock?

You can check YMAB's fair value in chart for subscribers. The fair value of Y-mAbs Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Y-mAbs Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YMAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Y-mAbs Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether YMAB is over valued or under valued. Whether Y-mAbs Therapeutics Inc is cheap or expensive depends on the assumptions which impact Y-mAbs Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YMAB.

What is Y-mAbs Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, YMAB's PE ratio (Price to Earnings) is -24.41 and Price to Sales (PS) ratio is 6.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YMAB PE ratio will change depending on the future growth rate expectations of investors.